A monoclonal antibody or an antibody fragment thereof, which specifically binds to a sugar chain in which a terminal sialic acid residue is bonded to galactose by an α2,3 bond, and is not dissociated from the sugar chain after the binding to the sugar chain in which the terminal sialic acid residue is bonded to the galactose by the α2,3 bond, wherein the amino acid sequence of complementarity-determining region 1 of the heavy chain variable region of the antibody or the antibody fragment thereof comprises an amino acid sequence set forth in SEQ ID NO: 1, the amino acid sequence of CDR2 of the VH comprises an amino acid sequence set forth in SEQ ID NO: 2. the amino acid sequence of CDR3 of the VH comprises an amino acid sequence set forth in SEQ ID NO: 3, the amino acid sequence of CDR1 of the light chain variable region comprises an amino acid sequence set forth in SEQ ID NO: 4, the amino acid sequence of CDR2 of the VL comprises an amino acid sequence set forth in SEQ ID NO: 5, and the amino acid sequence of CDR3 of the VL comprises an amino acid sequence set forth in SEQ ID NO: 6, and wherein the amino acid sequence of the VH of the antibody or the antibody fragment thereof comprises an amino acid sequence set forth in SEQ ID NO: 13 and wherein the amino acid sequence of the VL of the antibody or the antibody fragment thereof comprises an amino acid sequence set forth in SEQ ID NO: 14, or wherein the amino acid sequence of CDR1 of the VH of the antibody or the antibody fragment thereof comprises an amino acid sequence set forth in SEQ ID NO: 7, the amino acid sequence of CDR2 of the VH comprises an amino acid sequence set forth in SEQ ID NO: 8, the amino acid sequence of CDR3 of the VH comprises an amino acid sequence set forth in SEQ ID NO: 9, the amino acid sequence of CDR1 of the VL comprises an amino acid sequence set forth in SEQ ID NO: 10, the amino acid sequence of CDR2 of the VL comprises an amino acid sequence set forth in SEQ ID NO: 11, and the amino acid sequence of CDR3 of the VL comprises an amino acid sequence set forth in SEQ ID NO: 12, and wherein the amino acid sequence of the VH of the antibody or the antibody fragment thereof comprises an amino acid sequence set forth in SEQ ID NO: 15 and wherein the amino acid sequence of the VL of the antibody or the antibody fragment thereof comprises an amino acid sequence set forth in SEQ ID NO: 16. which specifically binds to a sugar chain in which a terminal sialic acid residue is bonded to galactose by an α2,3 bond, and is not dissociated from the sugar chain after the binding to the sugar chain in which the terminal sialic acid residue is bonded to the galactose by the α2,3 bond, wherein the amino acid sequence of complementarity-determining region 1 of the heavy chain variable region of the antibody or the antibody fragment thereof comprises an amino acid sequence set forth in SEQ ID NO: 1, the amino acid sequence of CDR2 of the VH comprises an amino acid sequence set forth in SEQ ID NO: 2. the amino acid sequence of CDR3 of the VH comprises an amino acid sequence set forth in SEQ ID NO: 3, the amino acid sequence of CDR1 of the light chain variable region comprises an amino acid sequence set forth in SEQ ID NO: 4, the amino acid sequence of CDR2 of the VL comprises an amino acid sequence set forth in SEQ ID NO: 5, and the amino acid sequence of CDR3 of the VL comprises an amino acid sequence set forth in SEQ ID NO: 6, and wherein the amino acid sequence of the VH of the antibody or the antibody fragment thereof comprises an amino acid sequence set forth in SEQ ID NO: 13 and wherein the amino acid sequence of the VL of the antibody or the antibody fragment thereof comprises an amino acid sequence set forth in SEQ ID NO: 14, or wherein the amino acid sequence of CDR1 of the VH of the antibody or the antibody fragment thereof comprises an amino acid sequence set forth in SEQ ID NO: 7, the amino acid sequence of CDR2 of the VH comprises an amino acid sequence set forth in SEQ ID NO: 8, the amino acid sequence of CDR3 of the VH comprises an amino acid sequence set forth in SEQ ID NO: 9, the amino acid sequence of CDR1 of the VL comprises an amino acid sequence set forth in SEQ ID NO: 10, the amino acid sequence of CDR2 of the VL comprises an amino acid sequence set forth in SEQ ID NO: 11, and the amino acid sequence of CDR3 of the VL comprises an amino acid sequence set forth in SEQ ID NO: 12, and wherein the amino acid sequence of the VH of the antibody or the antibody fragment thereof comprises an amino acid sequence set forth in SEQ ID NO: 15 and wherein the amino acid sequence of the VL of the antibody or the antibody fragment thereof comprises an amino acid sequence set forth in SEQ ID NO: 16.